Intellipharmaceutics International Inc. (IPCIF)
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1000 - 0.1000 |
| 52 Week Range | 0.0100 - 0.1400 |
| Volume | |
| Avg. Volume | 5,603 |
| Market Cap | 3.309M |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | Jun 03, 2024 - Jun 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREIntellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and ...
- ACCESSWIRE
Intellipharmaceutics Announces Cease Trade Order
TORONTO, ON / ACCESSWIRE / March 6, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic ...
- ACCESSWIRE
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and ...
